Astrazeneca Vaccinations
-
{
- All
- News
-
Vaccine Trial Patient In US Sues AstraZeneca, Claiming She Was Left "Permanently Disabled"
An American woman who claims she was "permanently disabled" after taking part in the US clinical trial of AstraZeneca's COVID-19 vaccine is suing the drug maker because they failed to provide her with medical care for her side effects.
-
AstraZeneca Drops Covid Vaccine Weeks After Rare Side Effect Report
AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine, days after it was reported that the British pharmaceutical company admitted that the jab can cause rare side effects.
-
"Sympathy Goes Out...": AstraZeneca Amid Vaccine's Side Effects Concerns
Amid concerns regarding potential side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant on Tuesday reiterated its commitment to patient safety.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
AstraZeneca Covid Jab Linked To Higher Risk Of Rare Blood Clot, Finds Study
AstraZeneca's Covid vaccine has been linked to a 30-percent higher risk of getting a very rare blood clotting condition compared to the Pfizer jab, a large international study said on Thursday.
-
AstraZeneca Claims Positive Medicine Trial For "Severe" Covid
A treatment for people at risk of death from coronavirus has revealed good results in a late-stage trial, its maker AstraZeneca announced Wednesday.
-
AstraZeneca, Given As Booster, Gives Higher Antibodies Against Omicron
AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a th
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
Next Virus Could Be More Lethal, Warns Oxford University Covid Vaccine Creator
The scientist behind the creation of the Oxford/AstraZeneca vaccine, administered in India as Covishield to protect against COVID-19, on Monday warned that the next virus to hit humankind may be even more lethal and contagious.
-
Britain's Prince Charles To Open New AstraZeneca Research Centre
Britain's Prince Charles will formally open a new 1 billion pound AstraZeneca research and development (R&D) facility on Tuesday, as the company aims to fuel the growth of its drug pipeline.
-
AstraZeneca Selling Covid Vaccine At Profit After 3rd Quarter Loss
British pharmaceutical giant AstraZeneca said Friday it has begun to sell its Covid vaccine at a profit as the company posted a third quarter loss on higher costs.
-
EU Commissioner Hopeful People Vaccinated With AstraZeneca Can Enter US
While Washington has not authorized the AstraZeneca vaccine against Covid-19, a European commissioner on Monday expressed hope that travelers from the continent inoculated with the jab will soon be able to enter the United States.
-
Nerve Disorder Listed As "Very Rare" Side Effect Of AstraZeneca Vaccine
The European Medicines Agency has listed the neurological disorder Guillain-Barre syndrome, which can cause temporary paralysis, as a "very rare" side effect of the AstraZeneca Covid-19 vaccine.
-
Clotting Linked With AstraZeneca Vaccine Very Rare, Says Oxford Study
The very rare blood clots that can be caused by the Oxford/AstraZeneca coronavirus vaccine can be aggressive and deadly but is very rare, leading scientists have concluded in the findings of the first study of its kind on Thursday.
-
Pfizer, AstraZeneca Vaccine Antibody Levels May Decline In 2-3 Months: Lancet Study
Total antibody levels start to wane six weeks after complete immunisation with Pfizer and AstraZeneca vaccines, and can reduce by more than 50 per cent over 10 weeks, according to study published in The Lancet journal.
-
Vaccine Trial Patient In US Sues AstraZeneca, Claiming She Was Left "Permanently Disabled"
An American woman who claims she was "permanently disabled" after taking part in the US clinical trial of AstraZeneca's COVID-19 vaccine is suing the drug maker because they failed to provide her with medical care for her side effects.
-
AstraZeneca Drops Covid Vaccine Weeks After Rare Side Effect Report
AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine, days after it was reported that the British pharmaceutical company admitted that the jab can cause rare side effects.
-
"Sympathy Goes Out...": AstraZeneca Amid Vaccine's Side Effects Concerns
Amid concerns regarding potential side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant on Tuesday reiterated its commitment to patient safety.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
AstraZeneca Covid Jab Linked To Higher Risk Of Rare Blood Clot, Finds Study
AstraZeneca's Covid vaccine has been linked to a 30-percent higher risk of getting a very rare blood clotting condition compared to the Pfizer jab, a large international study said on Thursday.
-
AstraZeneca Claims Positive Medicine Trial For "Severe" Covid
A treatment for people at risk of death from coronavirus has revealed good results in a late-stage trial, its maker AstraZeneca announced Wednesday.
-
AstraZeneca, Given As Booster, Gives Higher Antibodies Against Omicron
AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a th
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
Next Virus Could Be More Lethal, Warns Oxford University Covid Vaccine Creator
The scientist behind the creation of the Oxford/AstraZeneca vaccine, administered in India as Covishield to protect against COVID-19, on Monday warned that the next virus to hit humankind may be even more lethal and contagious.
-
Britain's Prince Charles To Open New AstraZeneca Research Centre
Britain's Prince Charles will formally open a new 1 billion pound AstraZeneca research and development (R&D) facility on Tuesday, as the company aims to fuel the growth of its drug pipeline.
-
AstraZeneca Selling Covid Vaccine At Profit After 3rd Quarter Loss
British pharmaceutical giant AstraZeneca said Friday it has begun to sell its Covid vaccine at a profit as the company posted a third quarter loss on higher costs.
-
EU Commissioner Hopeful People Vaccinated With AstraZeneca Can Enter US
While Washington has not authorized the AstraZeneca vaccine against Covid-19, a European commissioner on Monday expressed hope that travelers from the continent inoculated with the jab will soon be able to enter the United States.
-
Nerve Disorder Listed As "Very Rare" Side Effect Of AstraZeneca Vaccine
The European Medicines Agency has listed the neurological disorder Guillain-Barre syndrome, which can cause temporary paralysis, as a "very rare" side effect of the AstraZeneca Covid-19 vaccine.
-
Clotting Linked With AstraZeneca Vaccine Very Rare, Says Oxford Study
The very rare blood clots that can be caused by the Oxford/AstraZeneca coronavirus vaccine can be aggressive and deadly but is very rare, leading scientists have concluded in the findings of the first study of its kind on Thursday.
-
Pfizer, AstraZeneca Vaccine Antibody Levels May Decline In 2-3 Months: Lancet Study
Total antibody levels start to wane six weeks after complete immunisation with Pfizer and AstraZeneca vaccines, and can reduce by more than 50 per cent over 10 weeks, according to study published in The Lancet journal.
